The large scale antibacterial, antifungal and anti-phage efficiency of Petamcin-A: new multicomponent preparation for skin diseases treatment

Mikayel Ginovyan¹, Andranik Keryan¹, Inga Bazukyan¹, Petros Ghazaryan² and Armen Trchounian¹*

Abstract

Background: Human and animal skin diseases of bacterial, fungal and viral nature and their complications are widespread and globally cause a serious trouble. Their prevalence is increasing mainly due to drug resistance. Consequently, demand has increased for new effective antimicrobial drugs, which also should be less toxic, possess a wider spectrum of action and be economically more beneficial. The goal was to investigate antibacterial, antifungal and anti-phage activity of Petamcin-A-a new multicomponent preparation. It contains acetic acid and hexamethylenetetramine as main active antimicrobial components, as well as phosphatidylcholine, tocopheryl acetate and glycerol as excipients.

Methods: Bacteriostatic activity and minimal inhibitory concentrations of the preparation against various test-organisms were determined by agar well diffusion assay. Antifungal activity was tested by agar dilution assay. To explore anti-phage activity double agar overlay plaque assay was used. Nystatin, chlorhexidine and acetic acid were used as control agents for comparative analysis. Statistical analysis was done with GraphPad Prism 5.03 or R 3.1.0 software.

Results: The results showed a higher activity of Petamcin-A against all bacterial and fungal test strains compared with its components or control agents. The preparation was more effective against tested gram-positive bacteria than gram-negative ones. Petamcin-A expressed bactericidal activity against almost all test strains. In addition, the preparation demonstrated high activity against T4 phage of Escherichia coli C-T4 completely inhibiting its growth. 5-fold diluted Petamcin-A also exhibited considerable activity reducing phage concentration by 2.6 Log₁₀.

Conclusions: Petamcin-A has a high antimicrobial activity against all tested strains of bacteria, yeasts and moulds. The preparation also exhibited high anti-phage activity. Moreover, taking into account that Petamcin-A has no observable toxicity on skin and its components are not expensive, it can be advantageous for management of various skin medical conditions.

Keywords: Acetic acid, Petamcin-A, Antimicrobial activity, Anti-phage activity, Biologically active compounds, Skin infectious disease

* Correspondence: Trchounian@ysu.am
1Department of Microbiology, Plants and Microbes Biotechnology, Faculty of Biology, Yerevan State University, Yerevan, Armenia
Full list of author information is available at the end of the article

© 2015 Ginovyan et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction

The prevalence of bacterial, fungal and viral skin infectious diseases and their complications are continuously increasing throughout the world. Because of the limited number of therapeutic methods this problem is one of the most urgent challenges in biology and medicine [1–3]. The frequency of these diseases is particularly higher in developing countries, mainly due to lower level of their healthcare systems as well as inability of many patients to receive expensive treatment for a long period of time [4]. Treatment difficulties of these diseases mainly are a consequence of acquired resistance development by microorganisms towards commonly used drugs [5–8]. Therefore, it is not a coincidence that 21st century is considered as post-antibiotic era in order to highlight importance of the problem [9]. Another serious challenge of the field is the acquisition of pathogenicity by microorganisms previously considered as non-pathogenic, which could happen due to various mutations, increasing number of immune-compromised patients, etc. [10]. Hence, the development of new, more efficient drugs is of utmost importance. On the other hand, it is essential to create economically more beneficial antimicrobials affordable for a population living in poor regions. Another criterion of new antimicrobials is a wide spectrum of action, considering the fact that many skin infections are caused by various microbial associations [11].

Both topical and systemic antimicrobial agents could be used for treatment of skin infections depending on various conditions (infection stage, size of infected area, type of pathogens, depth of infections, etc.). Both of them have their advantages and disadvantages [12, 13]. Particularly, topical antimicrobials help to avoid systemic toxicity and side effects as well as to decrease the possibility of resistance acquisition. Moreover, they allow to apply high concentration of antimicrobials directly on the zone of infection. The main disadvantage of topical agents is a difficulty to supply active agents to affected area, especially during deep skin infections [12, 13].

The object of this study was the multi-component liquid preparation Petamcin-A, which was developed and patented as topical antifungal agent [14]. Preparation contains acetic acid, hexamethylenetetramine, phosphatidylcholine, tocopheryl acetate and glycerol [14]. It has been successfully used during recent years for treatment of skin fungal diseases. This preparation does not have any noticeable toxicity and does not express any side effects [14, 15]. According to the preliminary data, under the influence of this preparation, statistically significant normalization of inflammatory reactions, stimulates cellular proliferation, and promotes the growth of connective tissue and regeneration of wound epithelium [15].

Two components of Petamcin-A-acetic acid and hexamethylenetetramine are responsible for its antimicrobial activity. Apart from antifungal activity, these compounds also possess antibacterial and antiviral activity and separately have been used for some applications [16, 17].

The main purpose of this study was to investigate antibacterial, antifungal and anti-phage properties of Petamcin-A. The obtained results could serve as a basis to develop its production for skin diseases treatment.

Materials and Methods

Microorganisms, growth conditions and antimicrobials used

Following microorganisms were used as test strains: bacteria Escherichia coli VKPM-M17 (Russian National Collection of Industrial Microorganisms at the Institute of Genetics and Selection of Industrial Microorganisms, Russia) (Laboratory control strain), Pseudomonas aeruginosa GRP3 (Soil and Water Research Institute, Iran) (Laboratory control strain), Bacillus subtilis WT-A1, isolated from metal polluted soils of Kajaran, Armenia, and Bacillus licheniformis WT (Department of Microbiology, Plants and Microbes Biotechnology, Yerevan State University (YSU), Armenia) (Laboratory control strains), Micrococcus luteus WT (Department of Microbiology, Plants and Microbes Biotechnology, YSU, Armenia) (Laboratory control strain), Salmonella typhimurium MDC 1754 (Microbial Depository Center, Armbiotechnology Scientific and Production Center, Armenia) (Laboratory control strain), Staphylococcus aureus MDC 5233 (Microbial Depository Center, Armbiotechnology Scientific and Production Center, Armenia) (Laboratory control strain), Lactobacillus delbrueckii subsp. lactis INRA-2010-4.2 (Department of Microbiology, Plants and Microbes Biotechnology, YSU, Armenia) (Probiotic strain), Lactobacillus delbrueckii subsp. bulgaricus INRA-2010-5.2 (Department of Microbiology, Plants and Microbes Biotechnology, YSU, Armenia) (Probiotic strain), Escherichia coli C-T4 (Elia Institute of Bacteriophage, Microbiology and Virology, Georgia), yeasts Candida albicans WT-174 isolated from infected vaginal microbiota of hospitalized patients (Department of Botany and Mycology, YSU, Armenia) (Clinical strain), Candida guilliermondii HP-17 (Department of Botany and Mycology, YSU Armenia) (Laboratory control strain), Debaryomyces hansenii WT (French National Institute for Agricultural Research (INRA), France) (Laboratory control strain), mould Mucor plumbeus WT and Geotrichum candidum WT (INRA, France) (Food pathogens), Penicillium aurantiogriseum
WT, isolated from spoiled food, *Trichoderma viride* WT, isolated from spoiled food, and *Aspergillus flavus* WT isolated from spoiled food (Department of Botany and Mycology, YSU, Armenia) (Food pathogens).

LB medium was used for cultivation of bacteria (peptone 10 g l\(^{-1}\), yeast extract 5 g l\(^{-1}\), sodium chloride 10 g l\(^{-1}\), sucrose 5 g l\(^{-1}\), MgSO\(_4\) 0.5 g l\(^{-1}\)), except *Lactobacillus delbrueckii* subsp. *lactis* and *Lactobacillus delbrueckii* subsp. *bulgaricus* which were cultivated in MRS (HiMedia, India). Beer wort agar (BWA) (Sigma-Aldrich, USA) and Sabouraud (glucose 40 g l\(^{-1}\), peptone 10 g l\(^{-1}\), yeast extract 5 g l\(^{-1}\)) media were used for cultivation of fungi. To obtain solid medium, agar (9 g l\(^{-1}\)) was added to nutrient media mentioned above.

12 % v/v acetic acid (one of the active compounds of Petamcin-A) as well as 30 μg ml\(^{-1}\) concentration of nystatin (“Borov Plant of Medical Preparations” JSC, Borisov, Belarus) dissolved in 5 % DMSO and 0.2 % w/v chlorhexidine gluconate (“Arsanit” LLC, Yervan, Armenia) were used as control agents for comparative analysis of the Petamcin-A activity.

**Determination of antibacterial and anti-yeast activity**

The bacteriostatic activity of Petamcin-A was tested by modified agar well diffusion assay [18]. 100 μl of overnight bacterial suspensions of indicator strains (adjusted to 10\(^6\) colony-forming unit (CFU) ml\(^{-1}\)) were poured into Petri dishes. Subsequently, 25 ml medium was added on top of them at 50 °C and gently shaken. After medium solidification wells with a diameter of 8 mm were cut in it. 100 μl of compounds were added into wells. Plates were incubated at 37 °C except for *D. hansenii*, which was incubated at 27 °C. After 24 h zones of growth inhibition around the wells were measured.

For determination of minimal inhibitory concentrations (MIC) different concentrations of the preparation were tested by the method described above. The preparation was diluted in sterile distilled water. The maximal dilution which caused well defined growth inhibition zone of at least 2 mm was considered as MIC.

Bactericidal activity was determined by modified broth macrodilution method [19]. Approximately 1 mm\(^3\) parts of the medium from growth inhibition zones were cut off and subcultured in a liquid medium without antimicrobials. Tubes with media were incubated for 24 h. The growth of bacteria was estimated by measuring the optical density (OD) of culture media at 595 nm wavelength light using a spectrophotometer (GENESYS 10S UV–VIS, Thermo Scientific, USA). The absence of growth indicated about bactericidal activity of the preparation.

**Determination of anti-mould activity**

Anti-mould activity of the preparation was explored by agar dilution assay [18]. BWA plates were inoculated with test strains and kept at 27 °C for 10 day for complete spore formation. Then spores were separated from mycelia by washing with saline solution and poured into tubes. The concentration of spores was calculated with hemocytometer. The preparations were poured into small (5 ml) Petri dishes in appropriate concentrations, then 2 ml of BWA medium at 50 °C was added and gently shaken. After solidification 10\(^4\) CFU ml\(^{-1}\) fungal spores were added. Petri dishes were incubated for 10 day at 27 °C. The absence of growth indicated about anti-mould activity. Different concentrations of preparations were used in order to determine the MICs.

**Determination of anti-phage activity**

Anti-phage activity was determined by double agar overlay plaque assay [18]. Firstly, phage suspension was prepared. The concentration of plaque-forming units (PFU) was determined by the same method. In experimental group 30 μl of phage suspension at 10\(^{11}\) PFU ml\(^{-1}\) concentration and 30 μl of tested preparations were poured in a tube, while in the control group 30 μl saline solution was used instead of the preparations. The mixtures were incubated for 90 min at 37 °C. Then phage mixtures were diluted up to 10\(^{-8}\) in LB broth by serial ten-fold dilutions. *E. coli* C-T4 was pre-cultivated on slant agar then washed with LB broth and transferred into sterile tubes. The concentration of cells was determined measuring OD at 595 nm wavelength light. Appropriate dilution of phage (in volume of 1 ml) was poured into a tube. *E. coli* C-T4 (100 μl) was added and then 6 ml of LB containing 0.7 % agar at 50 °C was added on top. The mixture was shaken and poured in Petri dishes containing 20 ml 1.8 % LB agar. The plates were swirled, left to dry for 10 min at room temperature and incubated for 24 h at 37 °C. Viable phages form plaques on the seeded plates which could be enumerated. The number of viable phage particles in stock solution was determined by multiplying plaque numbers with dilution factor. The efficiency of the preparations was determined by comparing the amount of viable phage particles from experimental and control groups.

**Data processing**

All experiments were independently repeated three times. Obtained data were processed; standard deviations and standard errors were calculated using GraphPad Prism 5.03 (GraphPad Software, Inc.; USA) software. \(P\)-values were determined by Student's \(t\)-test with R 3.1.0 (The R foundation of statistical computing, Vienna, Austria, 2014) software.

**Results**

Antimicrobial activity of Petamcin-A against different test strains was investigated. The obtained data showed that Petamcin-A has a high antibacterial activity against
all tested strains (Table 1). Moreover, it was more effective compared with control agents. Petamcin-A was active against both prokaryotic and eukaryotic microorganisms. The preparation was more effective against tested gram-positive bacteria than gram-negative ones (see Table 1).

MICs of Petamcin-A and 12 % acetic acid against S. aureus and E. coli were determined (Table 2). Petamcin-A maintained its activity against S. aureus till 14 μl ml$^{-1}$ concentration, while its MIC for E. coli was 18 μl ml$^{-1}$. MICs of 12 % acetic acid were higher-33 μl ml$^{-1}$ and 50 μl ml$^{-1}$ for E. coli and S. aureus, respectively.

The results demonstrated the bactericidal activity of Petamcin-A against almost all tested bacterial strains, with the exception of B. subtilis WT-A1, against which the activity was bacteriostatic. Moreover, Petamcin-A retained bactericidal activity against S. aureus till 33 μl ml$^{-1}$ concentration (Table 3). In case of E. coli, bactericidal activity of the preparation was observed till 100 μl ml$^{-1}$ concentration. Even though 12 % acetic acid showed bactericidal activity too, it lost this activity started from 200 μl ml$^{-1}$ concentration. This could testify that in low concentrations of Petamcin-A its component acetic acid is not the main cause of its bactericidal studies showed that Petamcin-A had higher activity against all tested yeast strains compared with control agents. It demonstrated maximal activity against D. hansenii (see Table 1). Moreover, Petamcin-A had fungicidal effect against all tested yeast strains and lost this activity starting from 100 μl ml$^{-1}$ concentration against C. albicans, and from 50 μl ml$^{-1}$ concentration against D. hansenii. Chlorhexidine and nystatin also expressed fungicidal activity against tested yeast strains, whereas 12 % acetic acid showed only static activity against C. albicans, but was fungicidal against C. guilliermondii and D. hansenii.

The investigations of anti-mould activity showed that both Petamcin-A and acetic acid inhibited the germination of all tested mould spores till 50 μl ml$^{-1}$ concentration. However, determination of MIC against T. viride showed that Petamcin-A inhibited spore germination even at 10 μl ml$^{-1}$ concentration, whereas 12 % acetic acid MIC for T. viride spores was 20 μl ml$^{-1}$.

Table 1 Antibacterial and anti-yeast activity of Petamcin-A in comparison with 30 μg ml$^{-1}$ nystatin, 0.2 % chlorhexidine and 12 % acetic acid

| Test strains       | Growth inhibition zones, mm |
|--------------------|----------------------------|
|                    | Petamcin-A | Chlorhexidine | Nystatin | Acetic acid |
| Escherichia coli   | 34 ± 0.9   | 21 ± 0.9     | 0        | 18 ± 0.5   |
| Pseudomonas aeruginosa | 36 ± 1     | 12 ± 0.7     | 0        | 25 ± 0.8   |
| Salmonella typhimurium | 44 ± 0.6   | 24 ± 1       | 0        | 31 ± 0.6   |
| Bacillus licheniformis | 54 ± 1.5   | 21 ± 0.6     | 0        | 35 ± 0.7   |
| Bacillus subtilis   | 43 ± 1.2   | 19 ± 0.5     | 0        | 23 ± 0.6   |
| Lactobacillus delbrueckii subsp. lactis | 42 ± 1.2   | 23 ± 0.7     | 0        | 22 ± 0.9   |
| Lactobacillus delbrueckii subsp. bulgaricus | 41 ± 1     | 22 ± 1       | 0        | 21 ± 0.6   |
| Micrococcus luteus  | 63 ± 1.5   | 31 ± 0.11    | 21 ± 0.9 | 45 ± 1     |
| Staphylococcus aureus | 56 ± 1     | 20 ± 0.8     | 0        | 29 ± 0.9   |
| Candida albicans    | 31 ± 0.8   | 25 ± 0.7     | 27 ± 1   | 22 ± 0.4   |
| Candida guilliermondii | 45 ± 0.1   | 28 ± 0.9     | 26 ± 0.8 | 24 ± 1.1   |
| Debaryomyces hansenii | 79 ± 2     | 40 ± 1.2     | 32 ± 1.2 | 35 ± 0.1   |

*All experiments were independently repeated three times. Mean values with standard deviations are presented, $p \leq 0.003$. For strains and methods, see Materials and methods.

Table 2 Determination of MICs of Petamcin-A and 12 % acetic acid against some test strains

| Strains            | MIC, μl ml$^{-1}$ |
|--------------------|-------------------|
|                    | Petamcin-A | Acetic acid |
| S. aureus          | 14        | 33         |
| E. coli            | 18        | 50         |
| D. hansenii        | 25        | 67         |
| T. viride          | 15        | 25         |

*All experiments were independently repeated three times. Mean values with standard deviations are presented, $p \leq 0.002$. For details, see Materials and methods.

Table 3 Determination of MBCs of Petamcin-A and 12 % acetic acid against some test strains

| Strains          | MBC, μl ml$^{-1}$ |
|------------------|-------------------|
|                  | Petamcin-A | Acetic acid |
| S. aureus        | 33        | 67         |
| E. coli          | 100       | 200        |
| C. albicans      | 100       | –          |
| C. guilliermondii| 100       | Undiluted  |
| D. hansenii      | 50        | Undiluted  |

*All experiments were independently repeated three times. Mean values with standard deviations are presented, $p \leq 0.002$. For details, see Materials and methods.
In addition, Petamcin-A demonstrated high activity against T4 phage of E. coli C-T4 completely inhibiting its growth. 12 % acetic acid also expressed anti-phage activity, but with less efficiency (Fig. 1). It caused only 2.4 Log$_{10}$ reduction of phage units. 200 μl ml$^{-1}$ concentration of Petamcin-A also demonstrated considerable activity reducing phage numbers by 2.6 Log$_{10}$ while the use of 100 μl ml$^{-1}$ concentration of 12 % acetic acid resulted in only 1.4 Log$_{10}$ reduction of E. coli C-T4.

Discussion

Petamcin-A is patented as antifungal preparation [14] for the treatment of various fungal skin infections. Its active antimicrobial components are acetic acid and hexamethylene tetramine which separately have been used in various medical applications, including the treatment of skin infections for a long time [16, 17, 20]. However, there is no data about their activity when applied together. Thus, it was very interesting to study the antibacterial and antiviral activity of Petamcin-A as a complex preparation.

Obtained data showed high efficiency of Petamcin-A against all tested strains, including bacteria, yeast, moulds and phages. Studies of antibacterial activity of the preparation illustrated that it was more effective than its component acetic acid and control agents. Moreover, its activity was higher against gram-positive bacteria in comparison with gram-negative ones. Such a difference was previously described for acetic acid [21]. At the same time there are no data indicating such differences for another active component of Petamcin-A—formaldehyde, which is released by decomposition of hexamethylene tetramine in even slightly acidic environment [22–24]. This allows speculating that this effect of Petamcin-A may be due to acetic acid.

The results allow to make some assumptions concerning Petamcin-A’s components activities. Particularly, it was determined, that in case of gram-negative bacteria growth inhibition zones by Petamcin-A were bigger than that by 12 % acetic acid (see Table 1). This difference was maximal (16 mm) for E. coli. Conversely, this difference in case of gram-positive bacteria was minimal (18 mm) for M. luteus, while it reached maximal value (27 mm) for S. aureus. Accordingly, it could be speculated that formaldehyde was more effective against gram-negative bacteria compared with gram-positive ones. Such a phenomenon was not described previously.

It is important to mention that Petamcin-A was particularly active against one of the most common causative agents of skin infections—S. aureus [25].

Petamcin-A killed all tested bacterial strains, except B. subtilis WT-A1. Bactericidal activity of the preparation is due to both acetic acid and formaldehyde. Many researchers reported about bactericidal activity of acetic acid and formaldehyde [13, 16, 17, 21, 26]. This means that both these components are responsible bactericidal activity of Petamcin-A. Two endospore forming bacteria were used in the study. Petamcin-A activity against B. licheniformis WT was bactericidal, whereas it was bacteriostatic against B. subtilis WT-A1. This may lead to speculations that there was a difference in the activity of Petamcin-A against sporulating and non-sporulating bacterial strains. However, B. subtilis WT-A1 strain was isolated from heavy metal polluted soils. Some studies state that genes responsible for heavy metal tolerance and antibiotic resistance are located in the same plasmid meaning there is a correlation between these two traits [27, 28]. Consequently, it can be assumed that B. subtilis WT-A1 strains have resistance against antimicrobials. Thus, the reason of Petamcin-A’s only bacteriostatic activity may be due to enhanced resistance of a particular strain, instead of its endospore forming ability. There is no evidence about acetic acid activity against bacterial spores, but many authors state about sporocidal activity of formaldehyde [21, 29, 30]. This affirms that Petamcin-A possesses activity against spores.

Petamcin-A showed high antifungal activity against tested three yeast and five mould strains. MIC determination of Petamcin-A and 12 % acetic acid against T. viride demonstrated that both active components of the preparation have their contribution in antifungal activity.

![Fig. 1 Anti-phage activity of Petamcin-A (PA) and 12 % acetic acid (AC) and their 200 μl ml$^{-1}$ concentrations against T4 phage of E. coli C-T4 after 90 min exposure time. Saline solution was used as a negative control. Concentrations of PFU of T4 phage of E. coli C-T4 were illustrated with Log10 values. Mean values with standard deviations are presented, $p \leq 0.005$. For details, see Materials and methods.](image-url)
Literature data confirms these results. For instance, high antifungal activity of acetic acid even at low concentrations against *Aspergillus flavus, Aspergillus luchuensis, Mucor spp.*, *Penicillium oxalicum* etc. was shown [31]. High fungicidal activity of formaldehyde was also reported [29]. The investigation of anti-phage activity showed that there was a considerable difference between activity of Petamcin-A and its component acetic acid. This suggests that antiviral activity of Petamcin-A is only partially due to acetic acid and, therefore, formaldehyde also have noticeable implementation in this activity. According to literature data acetic acid has been reported to be less effective against viruses compared with formaldehyde which has confirmed our results [26, 29]. It was shown that 6% acetic acid showed only 0.32 Log₁₀ reduction of *Poliowirus* after 5 min exposure time [17].

The mechanisms of Petamcin-A’s antimicrobial activity can be derived based on activities of its two components– acetic acid and formaldehyde. On the other hand, it is possible that together they could gain some new advantageous properties. Consequently, some further investigations are needed to understand the mode of Petamcin-A action as a complex preparation.

It is known, that mechanisms that underlie the activity of formaldehyde are due to its reactions with proteins and nucleic acids [29, 32]. Particularly, it alkylates amino and sulfhydryl groups of proteins, as well as nitrogen atoms of the purine rings of nucleic acids [32]. Therefore, this component is active against almost all types of microorganisms.

The modes of action of another active component of Petamcin-A–acetic acid against microbes have not been understood completely yet. But it is assumed that mainly its undissociated forms are responsible for antimicrobial activity [33, 34]. They could passively cross the cell wall and dissociate at neutral pH within the cells. This brings to a decrease of internal pH and cause further inhibitory effects on microbes. For example, interior acidic pH causes denaturation of acid-sensitive proteins and DNA, consumption of energy during regulation of internal pH, etc. It has also been proposed that acetic acid brings to interruption of the action of bacterial proton pumps responsible for ion regulation [33, 34].

The main part of this work was done using laboratory control strains. It would be interesting to investigate Petamcin-A’s activity against more clinical isolates and human pathogenic strains. This will be the next step of the work which could help to broaden its potential applications.

**Concluding remarks**

Petamcin-A has a high antimicrobial activity against all tested bacterial, yeast and mould strains. The preparation also exhibited high anti-phage activity. Furthermore, taking into account that Petamcin-A has not shown observable toxicity on skin and its components are not expensive, it can be advantageous for management of various skin medical conditions.

As far as Petamcin-A expressed antimicrobial activity against various groups of microorganisms, it also may have perspective to be used as a disinfectant but further investigations are needed.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MG, IB, AT proposed and designed the study; MG, AK carried out the experimental part of the manuscript. MG, AK, IB analyzed the generated data. IB, PG, AT helped to draft the manuscript and in critical revision. All authors read and approved the final manuscript.

**Author details**

1. Department of Microbiology, Plants and Microbes Biotechnology, Faculty of Biology, Yerevan State University, Yerevan, Armenia.
2. Department of Pharmaceutical Chemistry, Faculty of Chemistry, Yerevan State University, Yerevan, Armenia.

**Received: 28 December 2014 Accepted: 15 May 2015**

**Published online: 18 May 2015**

**References**

1. Godin B, Toulou T, Rubinstein E, Athamna A, Athamna M. A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation- an in vivo study. J Antimicrob Chemother. 2005;55:980–94.
2. Hernandez PO, Lema S, Tying SK, Mendoza N. Cefaroline in complicated skin and skin-structure infections. Infect Drug Resist. 2012;5:23–35.
3. Hafez MM, Maghrabi IA, Zaki NM. Toward an alternative therapeutic approach for skin infections: antagonistic activity of lactobacilli against antibiotic-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Probiotics Antimicrob Proteins. 2013;5:216–26.
4. World Health Organization. Epidemiology and management of common skin diseases in children in developing countries. Geneva: WHO; 2005.
5. Spellberg B, Talbot GH, Boucher HW, Bradley J, Gilbert D, Scheld WM, et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis. 2006;42:383–91.
6. Bobek LA, Stu H. MULC7 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action. Antimicrob Agents Chemother. 2003;47:643–52.
7. Torres HA, Hachern RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5:775–85.
8. Coogan MM, Fidel PJ, Komesu MC, Maeda N, Samarayake UP. (B1) Candida and mycotic infections. Adv Dent Res. 2006;19:130–8.
9. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva, Switzerland: WHO Press; 2014.
10. Burns T, Breathnach S, Cox N, Griffiths C. Rook’s textbook of dermatology. 8th ed. Wiley-Blackwell: Hoboken, New Jersey, USA; 2010.
11. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt). 2005;6:283–95.
12. Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs. 2003;5:35–46.
13. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis. 2009;49:1541–9.
14. Ghazaryan PA, Ghazaryan AP, Paronikyan RG. Treatment of fungal skin infections with “Petamcin-A”. Armenia, PAN 96168 by 08.08: Patent certificate for invention, issued by the Intellectual Property Agency; 1997. p. N 315.
15. Vardapetyan AR, Ghazaryan AP, Ghazaryan PA. Effect of Petamcin-A on the regeneration of the epithelium. Veterinariya. 2007;2:8–50 (in Russian).
16. Ryssel H, Kloeters O, Germann G, Schafer T, Wiedemann G, Oehlbauer M. The antimicrobial effect of acetic acid—an alternative to common local antiseptics? Burns. 2009;35:695–700.

17. Cortesia C, Vilchèze C, Bernut A, Contreas W, Gómez K, de Waard J, et al. Acetic acid, the active component of vinegar, is an effective tuberculocidal disinfectant. mBio. 2014;5(2):e00013–4.

18. Netrusov AI, Yegorova MA, Zakharchuk LM. Practical microbiology manuals. Moscow: Academia; 2005 (in Russian).

19. Barry AL, Craig WA, Nadler H, Reller BL, Sanders CC, Swenson JM. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1999.

20. Nagoda BS, Deshmukh SR, Wadher BJ, Patil SB. Acetic acid treatment of pseudomonal postoperative wound infection. J Hosp Infect. 1997;36:243–4.

21. Quinn PJ, Markey BK, Leonard FC, FitzPatrick ES, Fanning S, Hartigan P. Veterinary microbiology and microbial disease. Wiley-Blackwell: Hoboken, New Jersey, USA; 2011.

22. Greenwood D, Slack RCB. The antibacterial activity of hexamine (methenamine), hexamine hippurate and hexamine mandelate. Infection. 1981;9(5):223–7.

23. Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norby SR, et al. Kucers’ the use of antibiotics. Sixth edition: a clinical review of antibacterial, antifungal and antiviral drugs. Boca Raton, Florida, USA: CRC Press; 2010.

24. Musher DM, Griffith DP. Generation of formaldehyde from methenamine: effect of pH and concentration, and antibacterial effect. Antimicrob Agents Chemother. 1974;6:708–11.

25. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65:35–44.

26. Rutala WA, Barbée SL, Aguiar NC, Sobsey MD, Weber DJ. Antimicrobial activity of home disinfectants and natural products against potential human pathogens. Infect Control Hosp Epidemiol. 2000;21:33–8.

27. Silver S, Missa TK. Plasmid-mediated heavy metal resistances. Annu Rev Microbiol. 1988;42(1):717–43.

28. Calomiris JJ, Armstrong JL, Seidler RJ. Association of metal tolerance with multiple antibiotic resistance of bacteria isolated from drinking water. Appl Environ Microbiol. 1984;47(6):1238–42.

29. Rutala WA, Weber DJ. Healthcare infection control practices advisory committee. CDC, Atlanta, GA: Guideline for disinfection and sterilization in health care facilities; 2008.

30. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12:147–79.

31. Pandir RK, Jain P. Screening for antifungal activity of commercially available chemical food preservatives. Int J Pharm Sci Rev Res. 2010;5:25–7.

32. Maris P. Modes of action of disinfectants. Rev Sci Tech. 1995;14:47–55.

33. Ricke SC. Perspectives on the use of organic acids and short chain fatty acids as antimicrobials. Poult Sci. 2003;82:632–9.

34. Bradley EM, Williams JB, Schilling MW, Coggins PC, Crist C, Yoder S, et al. Effects of sodium lactate and acetic acid derivatives on the quality and sensory characteristics of hot-boned pork sausage patties. Meat Sci. 2011;88:145–50.